**Supplementary material**

**HIGH PROPORTION OF GUILLAIN-BARRÉ SYNDROME ASSOCIATED WITH CHIKUNGUNYA IN NORTHEAST BRAZIL.**

**Authors:** Aline de Moura Brasil Matos, MD; Fernanda Martins Maia Carvalho, MD, PhD; Danielle Lima Malta, PhD; Cleonisio Leite Rodrigues, MD, PhD; Alvina Clara Félix, M.Sc.; Claudio Sergio Pannuti, PhD; Amanda Dias da Rocha Lima, M.Sc.; Danilo Lucas Esposito. PhD; Leonilda Maria Barbosa dos Santos, PhD; Felipe von Glehn, MD, PhD, FAAN; Jeová Keny Baima Colares, MD, PhD; Benedito Antônio Lopes da Fonseca, MD, PhD; Augusto César Penalva de Oliveira, MD, PhD and Camila Malta Romano, PhD.

**Search terms:** [182] Guillain-Barre Syndrome; [142] Viral infections; [135] All infections; [145] Post-infectious; [132] Autoimmune diseases.

Fig. e-1. Patients flowchart.

Legends: GBS= Guillain-Barré Syndrome; CHIKV-GBS= GBS cases associated with Chikungunya virus; CDC= Centers for Disease Control and Prevention. \*Mixed neurological syndromes where one case of polyneuropathy + encephalitis and two cases of polyneuropathy + encephalomyelitis.

|  |
| --- |
| Table e-1. Clinical characteristics, recovery and outcomes of patients with CHIKV-associated Guillain-Barré Syndrome. |
| Legend: Abbreviations: y=years; d=days; MRC= Medical Research Council scale; MV= mechanical ventilation; EMG= electromyography; CHIKV= Chikungunya virus; ELISA= Enzyme-Linked Immunosorbent assay; Adm= admission; mo.= months; Pt= protein; NA= not available; NR= negative result. \*Patient 1 was also positive in serum for ZIKV and DENV IgM and IgG, patient 3 was also positive in serum for DENV IgM and IgG. † Hadden's electrophysiology criteria for GBS was adopted. |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Patient | Age, y | Sex | Systemic symptoms to neurologic symptoms, d  | Hugues Scale |   | MRC Scale | MV | CSF | EMG† | CHIKV ELISA |
|  |  |  |  | Adm | 6 mo. |  | Adm | 6 mo. |  | Cells/µl | Pt, mg/dl |  | Serum | CSF |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 1\* | 54 | M | 5 | 4 | 0 |  | 46 | 60 | No | 1 | 116.7 | Primary demyelinating | IgM + | NR |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 2 | 23 | F | 8 | 2 | 0 |  | 56 | 60 | Yes | 5 | 10.4 | Primary demyelinating | IgM + | NR |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 3\* | 43 | F | No symptoms | 4 | 1 |  | 28 | 60 | No | 1 | 124 | Primary demyelinating | IgM + | NR |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 4 | 26 | M | 16 | 4 | 0 |  | 46 | 60 | No | 2 | 93.4 | Primary axonal | IgM + | NR |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 5 | 59 | F | No symptoms | 4 | 1 |  | 24 | 60 | No | 7 | 324.1 | Primary demyelinating | IgM + | NR |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 6 | 51 | M | 11 | 3 | 1 |  | 40 | 60 | Yes | 17 | 87.3 | Primary demyelinating | IgM + | NR |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 7 | 47 | M | 7 | 4 | 1 |  | 38 | 60 | No | 2 | 226 | Primary demyelinating | IgM + | IgM+ |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 8 | 56 | F | 6 | 4 | 0 |  | 20 | 60 | No | NA | NA | Primary demyelinating | IgM + | NA |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 9 | 38 | M | 17 | 3 | 1 |  | 20 | 60 | No | 5 | 59.2 | Primary axonal | IgM + | NR |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

